CVRx, Inc. (NASDAQ:CVRX) on Thursday initiated the BENEFIT-HF clinical trial, a landmark randomized study supported by CMS Category B IDE coverage and designed to evaluate the impact of Barostim in a significantly expanded heart failure population.Barostim is an implantable device that delivers electrical signals to baroreceptors (sensory neurons that monitor blood pressure) located on the carotid artery, increasing baroreflex signaling, rebalancing the autonomic nervous system, and improving heart failure ...